Full-Time
Development Data & Biological Assessment Specialist
FMC
5,001-10,000 employees
Develops pesticides and sustainable agricultural solutions
No salary listed
Frankfurt, Germany
Remote
Remote within Europe.
Bachelor's, Master's
 Biology & Biotech (1) |
|---|
Get referred to FMC
See people who can refer or advise you
- A Bachelor's or Master's degree in Crop Science, Biology, Agronomy, Agricultural Sciences, Life Sciences, Biotechnology, Data Science, or a related discipline.
- Experience in biological data management, research and development data support within crop science, Biological Assessment Dossier preparation, and project coordination in multidisciplinary, global teams.
- Proficiency in data analytics, reporting, and visualization tools, with experience in data management systems and knowledge of data quality and governance principles.
- Working knowledge of plant protection regulations, registration requirements, or biological dossier preparation.
- Strong analytical, problem-solving, organizational, and stakeholder management skills, with an understanding of project management principles and tools.
- Interest in artificial intelligence, automation, digital innovation, and continuous process improvement, supported by strong communication and collaboration skills.
- Drive the quality, integrity, validation, and accessibility of biological development data by performing data quality checks, troubleshooting issues, and managing biological trial data from multiple sources.
- Prepare, analyze, and present biological data to support seasonal results reviews, Biological Assessment Dossier preparation, and data-driven decision-making throughout the product development lifecycle.
- Lead and coordinate Biological Assessment Dossier activities from project initiation through submission, monitoring timelines, deliverables, and data readiness while identifying risks and mitigation actions.
- Partner with Regional Technical Managers and regulatory stakeholders to provide biological data expertise, ensure regulatory readiness, and support successful product development.
- Identify opportunities for automation, process optimization, and standardization of biological data management practices.
- Develop dashboards, visualizations, and artificial-intelligence-enabled solutions to enhance project tracking, improve data accessibility, and support operational excellence.
- Experience with SQL and/or Power BI.
FMC develops and supplies crop protection products, including herbicides, insecticides, and fungicides, plus formulations and technologies that help protect crops from pests and diseases. Its products work by using chemical active ingredients and tailored formulations that control pests while aiming to minimize environmental impact; the company emphasizes science-driven solutions to improve efficacy and safety in farming. Compared with competitors, FMC leverages a long history (over a century) and a clear focus on sustainable technologies that protect both crops and the environment, with ongoing discovery of new actives and innovative formulations. The company’s goal is to help feed the world’s growing population by delivering effective crop protection that is better for the planet.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Philadelphia, Pennsylvania
Founded
1883
Get referred to FMC
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 adjusted EBITDA hit $153 million, above guidance, despite 17% revenue decline.
- FMC raised 2026 free cash flow guidance to $75 million-$225 million after rimisoxafen.
- Closing India, Newark, Corteva, and Tessenderlo transactions targets roughly $1 billion debt reduction.
What critics are saying
- FMC cut 2026 revenue guidance to $3.5 billion-$3.7 billion on July 29, 2026.
- Secured notes and tighter covenants on June 5, 2026, trap FMC in expensive refinancing.
- If 2027 pricing stays weak, FMC faces a distress sale before 2031 maturities.
What makes FMC unique
- FMC’s proprietary pipeline produced Isoflex, fluindapyr, and rimisoxafen licensing deals in 2026.
- EU approved Isoflex on April 6, 2026, giving FMC a real commercial catalyst.
- Tessenderlo’s June 30, 2026 $400 million stake validates FMC’s asset base and brand portfolio.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Family Planning Benefits
Mental Health Support
Company News
FMC Corporation reported second quarter 2026 revenue of $867 million, down 17% year-over-year, with adjusted EBITDA of $153 million exceeding guidance. Excluding India, revenue fell 20% to $841 million, with organic revenue declining 22%. The company posted a GAAP net loss of $187 million, or $1.49 per diluted share. Adjusted earnings per share reached $0.26, down 62% from the prior year. Cash from operations rose significantly to $363 million, up $297 million year-over-year. FMC lowered its full-year outlook due to challenging macroeconomic conditions. The company now expects revenue excluding India of $3.50 billion to $3.70 billion and adjusted EBITDA between $620 million and $680 million. Free cash flow guidance increased to $75 million to $225 million, including a $200 million upfront licensing payment for rimisoxafen.
Tessenderlo Group has agreed to invest $400 million in FMC Corporation for a 20% stake at $13.30 per share, valuing the agricultural sciences company at approximately $2 billion. The transaction concludes FMC's strategic review initiated in February 2026 and supports its $1 billion debt reduction target. The Belgian industrial group described the investment as part of its strategy to acquire cornerstone minority stakes in high-quality agricultural companies. FMC said the agreement aligns with its operational plans, including advancing its R&D pipeline and commercialising new innovations. The deal follows recent FMC initiatives including a $1.2 billion bond offering, the $252 million sale of its India business, and a $200 million prepayment from Corteva. The transaction requires regulatory approvals and customary closing conditions.
FMC Corporation, a global agricultural sciences company, has reached a definitive agreement with Belgian industrial group Tessenderlo Group for a $400 million minority equity investment at $13.30 per share. Upon completion, Tessenderlo Group will own approximately 20% of FMC's outstanding shares. The transaction concludes FMC's strategic options review announced in February 2026. FMC will use the proceeds to pay down debt, reaching its approximately $1 billion debt paydown target. Recent actions include raising $1.2 billion in secured bonds, selling its India commercial business for $252 million, and securing a $200 million prepayment from a Corteva agreement. The deal is subject to regulatory approvals. BofA Securities and Goldman Sachs advised FMC, whilst Stibbe and Sullivan & Cromwell advised Tessenderlo Group.
FMC Corporation has raised $750 million through senior secured notes due 2031, issued under Regulation S and Rule 144A with guarantees. The fixed-income offering aims to strengthen the company's financial position and provide flexibility for operations, debt management and potential growth initiatives. The financing comes alongside a sharp dividend cut announced in April 2026, from $0.58 to $0.08 per share, signalling management's focus on cash preservation and balance sheet repair. FMC faces elevated leverage and weak interest coverage, making debt management the key near-term catalyst. Whilst the bond issue may ease short-term liquidity pressure, the company's investment narrative still depends on restoring profitability and cash generation in its crop protection business. Some analysts project FMC could reach $4.5 billion in revenue and $429 million in earnings.
FMC Corporation reported first-quarter 2026 sales of $758.6 million and a net loss of $281.3 million, whilst maintaining its full-year 2026 sales guidance of $3.6 billion to $3.8 billion. The company is navigating a planned mid-single-digit price decline and the removal of India sales from its portfolio. Despite the quarterly loss, management's decision to reaffirm annual guidance signals confidence in volume growth and new product launches to offset pricing pressure and the India exit. The company faces ongoing challenges from elevated leverage and weak interest coverage. The narrative projects FMC could reach $4 billion in revenue and $286.1 million in earnings by 2029, with a fair value estimate of $17.53 representing 33% upside. The stock has fallen 11.6% following the announcement.